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Heterotrimeric G proteins, composed of a, b, and g subunits, can transduce a variety of signals from seven-transmembrane-type
receptors to intracellular effectors. By whole-exome sequencing and subsequent mutation screening, we identified de novo hetero-
zygous mutations in GNAO1, which encodes a Gao subunit of heterotrimeric G proteins, in four individuals with epileptic enceph-
alopathy. Two of the affected individuals also showed involuntary movements. Somatic mosaicism (approximately 35% to 50% of
cells, distributed across multiple cell types, harbored the mutation) was shown in one individual. By mapping the mutation onto
three-dimensional models of the Ga subunit in three different complexed states, we found that the three mutants (c.521A>G
[p.Asp174Gly], c.836T>A [p.Ile279Asn], and c.572_592del [p.Thr191_Phe197del]) are predicted to destabilize the Ga subunit fold.
A fourth mutant (c.607G>A), in which the Gly203 residue located within the highly conserved switch II region is substituted to
Arg, is predicted to impair GTP binding and/or activation of downstream effectors, although the p.Gly203Arg substitution might
not interfere with Ga binding to G-protein-coupled receptors. Transient-expression experiments suggested that localization to the
plasma membrane was variably impaired in the three putatively destabilized mutants. Electrophysiological analysis showed that
Gao-mediated inhibition of calcium currents by norepinephrine tended to be lower in three of the four Gao mutants. These data
suggest that aberrant Gao signaling can cause multiple neurodevelopmental phenotypes, including epileptic encephalopathy and
involuntary movements.Introduction
Epileptic encephalopathy is a group of neurological disor-
ders characterized by severe and progressive cognitive and
behavioral impairments, which are most likely caused or
made worse by epileptic activity.1 Ohtahara syndrome
(OS [MIM 308350 and 612164]) is the most severe and
the earliest form of epileptic encephalopathy and is charac-
terized by tonic spasms mainly in the neonatal period,
seizure intractability, and a suppression-burst pattern on
electroencephalography (EEG).2 De novo mutations in
three genes, ARX (MIM 300382), STXBP1 (MIM 602926),
and KCNQ2 (MIM 602235), have been reported in individ-
uals with OS.3–6
Heterotrimeric guanine-binding proteins (G proteins)
are composed of a, b, and g subunits. In its basal state,
Ga is bound with guanosine diphosphate (GDP) and forms
the Gabg complex. When a seven-transmembrane-type
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(GTP) on the Ga subunit. Subsequently, GTP-bound Ga
dissociates from Gbg, and each of the two complexes acti-
vates distinct downstream effectors.7 Inmammals, Ga sub-
units are divided into four classes: Gai/o, Gaq/11, Gas, and
Ga12/13.
7 Gao, encoded by GNAO1 (MIM 139311), is
extremely abundant in brain tissue, where it can constitute
up to approximately 0.5% of membrane protein,8 suggest-
ing important roles in brain function. In fact, mice lacking
Gao show multiple neurological abnormalities, including
generalized tremor, occasional seizures, severe motor-
control impairment, hyperalgesia, and behavioral abnor-
malities with early postnatal lethality.9,10
In this study, de novo GNAO1mutations were identified
in four epileptic-encephalopathy-affected individuals,
three of whom were diagnosed with OS. In addition, two
of the four individuals showed involuntary movements,
suggesting that aberration of Gao can cause multiple
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Subjects and Methods
Subjects
Twelve individuals with OS were previously analyzed by whole-
exome sequencing (WES).3,11 In addition, we analyzed parental
samples from 5 of the 12 individuals by WES. Screening for
GNAO1 mutations was performed in 367 individuals with
epileptic encephalopathy (including 62 OS cases) by high-
resolution-melting (HRM) analysis (339 cases) and/or WES (100
cases). The diagnosis was made on the basis of clinical features
and characteristic patterns on EEG. Experimental protocols were
approved by the institutional review board of Yokohama City
University School of Medicine and Yamagata University Faculty
of Medicine. Informed consent was obtained from the families
of all individuals.
DNA Samples
Genomic DNA was obtained from peripheral-blood leukocytes by
standard methods. For detection of a mosaic mutation in indivi-
dual 2, genomic DNA from saliva and nails was isolated with an
Oragene DNA kit (DNA Genotek) and an ISOHAIR kit (Nippon
Gene), respectively.
WES
Genomic DNA was captured with the SureSelect Human All Exon
v.4 Kit (Agilent Technologies) and sequenced with four samples
per lane on an Illumina HiSeq 2000 (Illumina) with 101 bp
paired-end reads. Image analysis and base calling were performed
by Sequencing Control Software with Real-Time Analysis and
CASAVA software v.1.8 (Illumina). Exome data processing, variant
calling, and variant annotation were performed as previously
described.12–14 Reads were aligned to GRCh37 with Novoalign
(Novocraft Technologies). Duplicate reads were removed with
Picard, and local realignments around indels and base-quality-
score recalibration were performed with the Genome Analysis
Toolkit (GATK).13 Single-nucleotide variants and small indels
were identified with the GATK UnifiedGenotyper and were filtered
according to the Broad Institute’s best-practice guidelines v.3.
Not flagged as clinically associated, variants registered in
dbSNP135 were filtered. Filter-passed variants were annotated
with ANNOVAR.14 Pathogenic mutations detected by WES were
confirmed by Sanger sequencing.
Mutation Screening
Genomic DNA was amplified with an illustra GenomiPhi V2 DNA
Amplification Kit (GE Healthcare). Exons 1–8 covering theGNAO1
coding region of two transcript variants (transcript variant 1,
RefSeq accession number NM_020988.2, encoding Gao1; tran-
script variant 2, RefSeq accession number NM_138736.2, encod-
ing Gao2) were screened byHRM analysis. The last two exons differ
between the transcript variants. HRM analysis was performedwith
a Light Cycler 480 (Roche Diagnostics). Samples showing an
aberrant melting curve in the HRM analysis were sequenced.
PCR primers and conditions are shown in Table S1, available
online. All mutations not present in publically available databases
were verified with original genomic DNA and were searched for in
the variant database of our 408 in-house control exomes.
Deep Sequencing of a Mosaic Mutation
PCR products (length 178 bp) spanning the c.521A>G mutation
were amplified with the use of blood, saliva, and nail DNA samplesThe Americanfrom individual 2 and blood DNA samples from her parents as a
template. Adaptor ligation, nick repair, and amplification were
performed with the Ion Xpress Plus Fragment Library Kit (Life
Technologies) according to the manufacturer’s protocol (part no.
4471989 Rev. B). Indexing was carried out with the Xpress Barcode
Adapters 1–16 Kit (Life Technologies). Emulsion PCR and enrich-
ment steps were carried out with the Ion OneTouch 200 Template
Kit v.2 (Life Technologies) according to the manufacturer’s pro-
tocol (part no. 4478371 Rev. A). Sequencing of the amplicon
libraries was carried out on the Ion Torrent Personal Genome
Machine (PGM) with the Ion 314 sequencing chip and the Ion
PGM 200 Sequencing Kit (Life Technologies) according to the
recommended protocol (part no. 4474246 Rev. B). Torrent Suite
2.2 was used for all analyses. The percentage of mosaicism was
examined with the Integrative Genomics Viewer.15,16Expression Vectors
A full-length human GNAO1 cDNA clone (transcript variant 1,
encoding Gao1) was purchased from Kazusa DNA Research
Institute. Human GNAO1 cDNA was inserted into a pEF6/V5-
His-C vector for the introduction of a C-terminal V5 epitope
(Life Technologies). Site-directed mutagenesis using a KOD-Plus-
Mutagenesis kit (Toyobo) was performed for generating GNAO1
mutants, including c.521A>G (p.Asp174Gly), c.572_592del
(p.The191_Phe197del), c.836T>A (p.Ile279Asn), and c.607G>A
(p.Gly203Arg). A c.607_609delinsACA (p.Gly203Thr) mutant, in
which GTP binding was reversible in contrast to the WT,17 was
also generated to serve as the known loss-of-function mutant.18
All variant cDNAs were confirmed by Sanger sequencing.Immunofluorescence Microscopy
Mouse neuroblastoma 2A (N2A) cells were grown as previously
described.4 N2A cells on glass coverslips were transfected with
200 ng of plasmid DNA with the use of X-tremeGENE 9 DNA
Transfection Reagent (Roche Diagnostics). After 24 hr, cells were
fixed in PBS containing 4% paraformaldehyde for 15 min and
permeabilized in PBS containing 0.1% Triton X-100 for 5 min.
Cells were then blocked with 10% normal goat serum for
30 min. V5-tagged Gao1 was detected with a mouse V5 antibody
(1:200 dilution; Life Technologies) and Alexa-488-conjugated
goat anti-mouse IgG (1:1000 dilution; Life Technologies).
Coverslips were mounted with Vectashield (Vector Laboratories)
that contained DAPI and were visualized with an inverted
FV1000-D confocal microscope (Olympus).Structural Modeling and Free-Energy Calculations
We used FoldX software (version 3.0b5) to construct mutated
molecular structures and calculate the free-energy changes caused
by the mutations.19 We used crystal structures of the GDP-bound
inactive Gaibg heterotrimer (Protein Data Bank [PDB] 1GG2),
20
the nucleotide-free Gasbg in complex with agonist-occupied
monomeric b2 adrenergic receptor (b2AR) (PDB 3SN6),21 and the
transition-state analog of GTP (GDPþAlF4
)-bound Gaq in com-
plex with its effector phospholipase C-b (PLCb) (PDB 3OHM)22
as three-dimensional structure models of the Gao subunit in
different complexed states. Each of the mutations, corresponding
to p.Asp174Gly, p.Ile279Asn, or p.Gly203Arg in the human Gao
subunit, was introduced into the Ga subunit of each complex,
and the free-energy change upon the mutation was calculated
with FoldX software. Note that ligands included in the complexes
were ignored in the calculation because the FoldX energy functionJournal of Human Genetics 93, 496–505, September 5, 2013 497
Figure 1. De Novo GNAO1 Mutations in
Individuals with Epileptic Encephalopathy
Schematic representation of GNAO1,
including two transcript variants: tran-
script variant 1 (RefSeq NM_020988.2)
with nine exons and transcript variant 2
(RefSeq NM_138736.2) with eight exons.
The UTRs and coding regions are shown
in white and black rectangles, respectively.
Three mutations occurred in common
exons of two transcript variants, and one
mutation occurred uniquely in transcript
variant 1. Note that the electropherogram
of individual 2 suggested mosaicism of
the c.521A>G mutation, and a heterozy-
gous C>T change (rs1065375) was clearly
demonstrated. All mutations caused sub-
stitution or deletion of evolutionarily
conserved amino acids. Homologous se-
quences were aligned with the use of the
CLUSTALW web site.does not consider the contribution of ligands. The calculation was
repeated three times, and the resultant data were presented as an
average value with a SD.
Electrophysiology
For electrophysiological recording of calcium currents, we used
NG108-15 cells transfected with individual GNAO1 mutants.
Expression vectors were introduced by electroporation with the
Lonza Nucleofector device and the Cell Line Nucleofector Kit V
(Lonza) according to the manufacture’s protocol (program
X-023). Two micrograms of plasmid DNA was used per transfec-
tion. The transfected cells were plated on poly-L-lysine-coated
plastic coverslips (Cell Desk LF, MS-0113L; Sumitomo Bakelite) at
a density of about 5 3 104 cells/cm2 and cultured in Dulbecco’s
modified Eagle’s medium (DMEM) supplemented with 10% fetal
bovine serum (FBS). One day after transfection, the cells were
differentiated with DMEM supplemented with 10 mM prosta-
glandin E1, 50 mM IBMX, and 1% FBS for 3–7 days before
recording. During the culture period, half of the medium was
changed every other day.
The recording was made by the perforated whole-cell patch-
clamp technique with amphotericin B. Cells on coverslips were
perfused under an Olympus BX51W upright microscope
(Olympus) with a bath solution containing 140 mM NaCl,
5 mM CaCl2, 4 mM KCl, 1 mM MgCl2, 10 mM HEPES, 10 mM
TEACl, 8 mM glucose, and 0.0002 mM tetrodotoxin (pH 7.3
adjusted with NaOH). The patch pipette solution contained
100 mM CsCl, 10 mM EGTA, and 40 mM HEPES (pH 7.3 adjusted
with CsOH). Amphotericin B was added to the pipette solution at
2 ml/ml just before the experiments. The pipettes were fabricated
from borosilicate glass capillaries and had a resistance of 4–8 MU
when backfilled with the amphotericin-B-containing pipette solu-
tion. The recording was started when the series resistance was
reduced to <150 MU after gigaseal formation and clear cellular
capacitive surges had appeared. Voltage-gated calcium currents
were elicited by the application of 50 ms depolarizing pulses
to þ10 mV from the holding potential of 65 mV, recorded
with a Multiclamp 700B (Molecular Devices) controlled via498 The American Journal of Human Genetics 93, 496–505, September 5, 2013pCLAMP10 software (Molecular Devices),
filtered at 2 kHz, and sampled at 10 kHz
with 50% compensation for series resis-tance. Gao-mediated current inhibition was elicited by the
application of 10 mM norepinephrine via the bath solution. After
3–5 min, inhibition was assessed by measurement of the changes
in current density just before the end of the depolarizing pulses.
Recordings were made at room temperature.
Statistical multiple comparisons were made with ANOVA
followed by Dunnett’s post hoc test, and the threshold p value
for judging statistical significance was 0.05. The current inhibition
induced by norepinephrine in individual mutant-expressing
cells was assessed with a paired t test. The results are given as the
mean5 SEM.Results
GNAO1 Is Mutated in Individuals with Epileptic
Encephalopathy
We previously performed WES of 12 individuals with
OS.3,11 In this study, we analyzed parental samples from
5 of the 12 individuals by WES (mean RefSeq read depth
of 109) to systematically screen de novo or recessive
mutations. We found no recessive mutations in
SLC25A22 (MIM 609302), PNPO (MIM 610090), PNKP
(MIM 613402), PLCB1 (MIM 613722), or ST3GAL3 (MIM
615006), whose mutations were previously found in
epileptic encephalopathy,23–27 but we did find one or
two de novo mutations in each of the five trio exomes.
Among them, a de novo missense mutation (c.836T>A
[p.Ile279Asn]) in GNAO1 at 16q12.2 was identified in
individual 1. In the exome data of the other seven original
individuals, we also found in individual 2 a second
missense mutation (c.521A>G [p.Asp174Gly]), which
was confirmed as a de novo event by Sanger sequencing
(Figure 1). Moreover, GNAO1 mutation screening in 367
individuals with epileptic encephalopathy by HRM
analysis (339 individuals) and/or WES (100 individuals,
Table 1. Clinical Features of Individuals with a GNAO1 Mutation
Individual 1 Individual 2 Individual 3 Individual 4
Gender female female female female
Age 13 years 4 years, 1 month died at 11 months 8 years
Mutation c.836T>A (p.Ile279Asn) c.521A>G (p.Asp174Gly) c.572_592 del
(p.Thr191_Phe197 del)
c.607G>A (p.Gly203Arg)
Inheritance de novo de novo, somatic mosaic de novo de novo
Diagnosis Ohtahara syndrome Ohtahara syndrome Ohtahara syndrome epileptic encephalopathy
Initial symptom tonic seizure at 4 days series of tonic seizures at
29 days (tonic upgaze,
head nodding, extension
of all extremities)
series of tonic seizures at
2 weeks (resemble spasms)
opisthotonic posture,
developmental delay at
7 months
Initial EEG suppression-burst pattern
at 4 days
suppression-burst pattern
at 29 days
suppression-burst pattern
at 2 weeks
diffuse irregular spike-
and-slow-wave complex
at 5 years
Course of seizures tonic seizure at 5 years series of tonic seizures
at 9 months
tonic seizure at 10months focal seizure (tonic
upgaze), tonic seizure
at 5 years
Course of EEG multifocal sharp waves
at 1 year, 4 months;
suppression-burst pattern
at 5 years, 6 months
hypsarrhythmia at
3 months; diffuse spike-
and-slow-wave complex
at 1 year, 7 months; sharp
waves at frontal lobe
at 3 years, 9 months
hypsarrhythmia at
4 months
not done
Involuntary movement - - dystonia severe chorea, athetosis
Seizure control intractable (2–3 times
per day)
intractable (0–2 times
per day)
intractable intractable (several times
per day)
Development
Head control - þ - -
Sitting - - - -
Meaningful words - - - -
MRI normal at 1 month;
cerebral atrophy at
5 years, 6 months
delayed myelination
and thin corpus callosum
at 10 months
normal at 3 months delayed myelination at
1 year, 3 months; reduced
cerebral white matter,
thin corpus callosum at
4 years, 8 monthsmean read depth of 129) revealed two de novo mutations:
c.572_592 del (p.Thr191_Phe197del) in individual 3 and
c.607G>A (p.Gly203Arg) in individual 4 (Figure 1). One
mutation (c.836T>A) specifically affects GNAO1 transcript
variant 1, whereas the other three mutations affect both
transcript variants 1 and 2. Web-based prediction tools
suggested that these four mutations would be pathogenic
(Table S2). None of the four mutations was found in the
6,500 exomes of the National Heart, Lung, and Blood
Institute (NHLBI) Exome Sequencing Project Exome
Variant Server or among our 408 in-house control exomes.
Interestingly, exome data and Sanger sequencing indi-
cated that the c.521A>G mutation in individual 2 was
somatic mosaic (Figure 1 and Table S3). We confirmed
de novo somatic mosaicism of the c.521A>G mutation
by deep sequencing of PCR products amplified with
blood, nail, and saliva DNA from individual 2 and blood
DNA from her parents, showing that approximately
35%–50% of cells harbored the mutation (Table S3).The AmericanPhenotypes Associated with GNAO1 Mutations
Neurological features of four female individuals with
GNAO1 mutations are shown in Table 1. Three
individuals (individuals 1–3) developed tonic seizures
with suppression-burst pattern on EEG at the onset (range
4–29 days), leading to a diagnosis of OS. Individuals 2 and
3 transited to West syndrome, a common infantile
epileptic syndrome, as revealed by hypsarrhythmia on
EEG at 3–4 months of age (Figures 2A–2C). Individual 4
showed developmental delay and opisthotonic posture
at 7 months of age, and complex partial seizures with
epileptic discharge on EEG was observed at 5 years
(Figure 2D). Of note, two individuals showed involuntary
movements: individual 3 showed dystonia, and individual
4 displayed chorea and athetosis (Table 1 and Movie S1).
Brain MRI showed delayed myelination in individuals 2
and 4, cerebral atrophy or reduced cerebral white matter
in individuals 1 and 4, and thin corpus callosum in indi-
viduals 2 and 4 (Figures 2E–2I). Although seizures and EEGJournal of Human Genetics 93, 496–505, September 5, 2013 499
Figure 2. EEG and Brain MRI Features of Individuals with GNAO1 Mutations
(A and B) Interictal EEG of individual 3. A suppression-burst pattern was observed at 2 months of age (A), and transition to hypsarrhyth-
mia was observed at 4 months (B).
(C) Interictal EEG of individual 2 shows a suppression-burst pattern at 2 months.
(D) Interictal EEG of individual 4 shows a diffuse spike- or sharp-and-slow-wave complex at 5 years.
(E–I) T2-weighted axial images through the basal ganglia (E, H, and I) and T1-weighted axial (F) and sagittal (G) images.
Individual 1 showed cerebral atrophy at 5 years and 6 months (E). Individual 2 showed delayed myelination and thin corpus
callosum at 10 months (F and G). Individual 3 showed normal appearance at 3 months (H). Individual 4 showed reduced white matter
at 7 years (I).findings in two individuals with OS (individuals 2 and 3)
were temporarily improved by adrenocorticotropic
hormone therapy and valproic acid, all four individuals
had intractable epileptic seizures in spite of combinatory
therapy of antiepileptic drugs. All individuals had severe
intellectual disability and motor developmental delay,
and individual 3 died at 11 months because of respi-
ratory-tract obstruction. These data suggest that GNAO1
mutations can cause multiple neurodevelopmental phe-
notypes, including epileptic encephalopathy and involun-
tary movements.500 The American Journal of Human Genetics 93, 496–505, SeptembExpression of Mutant Gao1 in N2A Cells
To examine the mutational effect of four GNAO1 muta-
tions, we performed transient expression experiments in
N2A cells (Figure 3). C-terminally V5-epitope-tagged
wild-type (WT) Gao1, encoded by transcript variant 1,
was clearly localized in the cell periphery, as previously
reported.28 The p.Gly203Thr (with known loss of func-
tion)17 and p.Gly203Arg (in individual 4) altered proteins
were also localized in the cell periphery. In contrast, the
p.Thr191_Phe197del altered protein (in individual 3) accu-
mulated in the cytosolic compartment. The p.Asp174Glyer 5, 2013
Figure 3. Localization of V5-Tagged Gao1 Proteins in N2A Cells
Localization of WT and five altered Gao1 proteins in N2A cells.
The WT and p.Gly203Arg and p.Gly203Thr altered proteins
were localized to the cell periphery. In contrast, the
p.Thr191_Phe197del protein was localized to the cytosolic
compartment. The other p.Asp174Gly and p.Ile279Asn proteins
were localized to the cell periphery but were also observed in the
cytosol. The scale bars represent 10 mm.(individual 2) and p.Ile279Asn (individual 1) altered pro-
teins were localized to the cell periphery and had weak
signal in the cytosol, where more intense signal was
observed in the p.Asp174Gly protein. Similar patterns of
localization were observed for C-terminally AcGFP1-tagged
Gao1 (Figure S1). These localization patterns suggest that
the function of the p.Thr191_Phe197del altered protein
might be most severely affected.
Structural Impacts of the Mutations on the
Ga-Containing Complexes
To evaluate the impact of the GNAO1 mutations on
specific functions at the atomic level, we mapped the
substituted positions onto structures of the Ga subunit inThe Americancomplexed states representing the GDP-bound inactive
state, the nucleotide-free Gasbg in complex with the recep-
tor, and the GTP-bound active state. In the case of point
mutations, we further estimated free-energy changes of
the mutations by using FoldX software (version 3.0b5).19
The region corresponding to amino acid residues 191–
197 of human Gao1 is located in b strands and their
connecting loop region and is involved in interactions
with the G-protein-coupled receptor (GPCR) in the Gabg-
b2AR complex (Figure 4A and Figure S2A). Thus, the
deletion would affect secondary structure of the molecule
and would not only impair the interaction with GPCR
but also severely destabilize the Ga-subunit fold. The
substituted residues corresponding to Asp174 and Ile279
of the human Gao1 subunit are both buried inside the pro-
tein (Figure 4A) and are involved in hydrogen-bonding
and hydrophobic interactions, respectively (Figure S2B).
Therefore, the p.Asp174Gly and p.Ile279Asn substitutions
would destabilize the Ga-subunit fold, as supported by
FoldX calculations showing a more than 2 kcal/mol
increase in free-energy changes for these substitutions
(Figure 4B). It can be speculated that these altered proteins
tend to be misfolded or denatured in N2A cells and thus
have altered cellular localization (Figure 3).
The substituted residue corresponding to Gly203 of
human Gao1 is located within the highly conserved switch
II region, responsible for activation of downstream effec-
tors upon GTP binding (Figure 4A). Conformations of the
switch regions differ depending on the complex state of
the G protein. In the Gabg heterotrimer and the GDPþ
AlF4
-bound Ga-effector (PLCb) complex, the glycine resi-
dues are closely surrounded by the switch I region and GTP
(Figure 4A and Figure S2C). Thus, the p.Gly203Arg substi-
tution would cause steric hindrance between the arginine
side chain and the switch I region and/or GTP, destabiliz-
ing the complex, as supported by the FoldX calculations
showing a remarkable increase in free-energy change
upon the p.Gly203Arg substitution. By contrast, in the
Gabg-receptor (b2AR) complex, no substantial steric
hindrance was predicted from the structural modeling
and FoldX calculations (Figure 4B and Figure S2C). These
findings suggest that the p.Gly203Arg-substituted Ga
subunit would impair GTP binding and/or activation of
the downstream effectors, although it might still bind to
GPCR. This prediction was supported by previous reports,
in which GTP binding was weakened in the p.Gly203Thr
altered Ga.17 This also appears to be consistent with the
apparently normal cellular localization of the p.Gly203Arg
altered protein in N2A cells (Figure 3).
Electrophysiological Evaluation of Gao1 Mutants
It has been reported that N-type calcium channels are
inhibited, at least in part, via Gao-mediated signaling.
7
Using NG108-15 cells, in which norepinephrine-induced
calcium-current inhibition is mediated by Gao (Fig-
ure 5A),29 we analyzed functional properties of altered
Gao1. Compared with cells expressing WT Gao1 (theJournal of Human Genetics 93, 496–505, September 5, 2013 501
Figure 4. Structural Consideration of the
Ga Amino Acid Substitutions in Some
Complexed States
(A) Map of the amino acid substitution
sites on the crystal structures of Ga-
containing complexes: the GDP-bound
inactive Gaibg heterotrimer (left), the
nucleotide-free Gasbg in complex with
an agonist-occupied monomeric b2AR
(center), and the GDPþAlF4
-bound Gaq
in complex with its effector PLCb (right).
Molecular structures are shown as space-
filling representations (from PyMOL). Ga,
Gb, and Gg subunits are colored green,
yellow, and pink, respectively, and the
switch I and switch II regions in the Ga
subunit are in light green. The b2AR
(center) and PLCb (right) molecules are
colored brown. The substituted sites are
shown in red, and the indicated amino
acid numbers correspond to human Gao1
and, in parentheses, rat Gai1 (UniProtKB/
Swiss-Prot P10824) (left), bovine Gas
(UniProtKB/Swiss-Prot P04896) (center),
and mouse Gaq (UniProtKB/Swiss-Prot
P21279) (right). The illustrations above
each model show the orientation of each
subunit and the bound molecules.
(B) The free-energy change after each of
the amino acid substitutions was esti-
mated from calculations using FoldX
software. Each error bar represents an
average value with a SD.leftmost column in Figure 5B), NG108-15 cells expressing
the p.Thr191_Phe197del substitution revealed a signi-
ficant increase in calcium-current density before applica-
tion of norepinephrine (p < 0.05 by Dunnett’s post hoc
test; the second column from the right in Figure 5B), sug-
gesting that localization of the altered Gao1 might
affect calcium-channel activity. In cells expressing the
p.Asp174Gly substitution, a mild increase in the current
density was also suggested, although the difference was
not significant (the third column from the left in
Figure 5B). The other two substitutions had no effects on
the current (the second column from the left and the
rightmost column in Figure 5B). Treatment with 10 mM
norepinephrine reduced the calcium-current density by
19.0% 5 5.0% in cells expressing WT Gao1 (p < 0.01 by
paired t test; left panel in Figure 5A and the leftmost bar
in Figure 5C). A similar reduction was observed in cells ex-
pressing the p.Ile279Asn alteration (18.5% 5 3.5%, p <
0.01 by paired t test; the rightmost bar in Figure 5C). In
cells expressing the p.Thr191_Phe197del alteration, by
contrast, the reduction was obscured (12.1% 5 5.0%, not
significant by paired t test; right panel in Figure 5A and
the second bar from the right in Figure 5C). In cells
expressing the other two substitutions (p.Gly203Thr and
p.Asp174Gly), weaker current inhibition by norepine-
phrine was suggested (9.9% 5 3.8% and 11.1% 5 3.5%,
respectively; both were p< 0.05 by paired t test; the second
and third bars from the left in Figure 5C), although
compared with that in WT-expressing cells, the degrees502 The American Journal of Human Genetics 93, 496–505, Septembof inhibition in Gly203Thr- and p.Asp174Gly-expressing
cells did not reach statistical significance (not significant
by ANOVA). These data suggest that GNAO1 mutations
could hamper Gao-mediated signaling.Discussion
We successfully identified four de novo heterozygous
missense GNAO1 mutations in four individuals. All four
individuals showed severe intellectual disability andmotor
developmental delay, demonstrating that aberration of
Gao affects intellectual and motor development. In addi-
tion, all four individuals showed epileptic encephalopathy,
and two of them showed involuntary movements. Because
Gao-deficient mice show occasional seizures and general-
ized tremor,9,10 it is likely that epilepsy and involuntary
movement are two of the characteristic features caused
by GNAO1 mutations. Although Gao-deficient mice also
show hyperactivity and hyperalgesia,10 it is difficult to
evaluate whether our individuals had these symptoms
because of severe motor and cognitive impairment.
All four of these mutations, and especially two muta-
tions leading to the p.Thr191_Phe197del and p.Gly203Arg
substitutions, are predicted to affect Gao function by struc-
tural evaluation. In fact, transient expression in N2A cells
showed that localization of the p.Thr191_Phe197del
altered protein was dramatically changed to the cytosolic
compartment. Interestingly, two alterations (p.Ile279Asner 5, 2013
Figure 5. Evaluation of Gao-Mediated
Signaling in NG108-15 Cell Calcium-
Current Generation
(A) Representative traces of voltage-
gated calcium currents generated in
NG108-15 cells expressing WT (left) or
p.Thr191_Phe197del altered (right) Gao1.
Black and red traces represent the currents
before and 3 min after application of
10 mM norepinephrine, respectively.
(B) Current densities of the calcium cur-
rents before norepinephrine treatment in
cells expressingWTor altered Gao1. Scatter
plots represent the densities in individual
cells. Red squares and bars represent the
means and SEMs, respectively, of the
densities in individual cell groups (WT,
n ¼ 8; p.Gly203Thr, n ¼ 7; p.Asp174Gly,
n ¼ 8; p.Thr191_Phe197del, n ¼ 7;
p.Ile279Asn, n ¼ 7). Compared with
that in cells expressing WT Gao1, the
current density in cells expressing
p.Thr191_Phe197del increased signifi-
cantly (*p < 0.05 by Dunnett’s post
hoc test). The densities in the cells express-
ing other altered proteins did not vary
significantly.
(C) Comparison of norepinephrine-
induced inhibition of calcium currents in
cells expressing altered Gao1. Each error
bar represents the mean and SEM of
the percent decrease in current density
induced by application of 10 mMnorepinephrine. Paired t tests indicated that the inhibition induced by norepinephrine was significant
in cells expressing WT (n ¼ 8) and p.Gly203Thr (n ¼ 7), p.Asp174Gly (n ¼ 8), and p.Ile279Asn (n ¼ 7) altered proteins (**p < 0.01 and
*p < 0.05), but not in cells expressing p.Thr191_Phe197del (n ¼ 7). Although there was some tendency for decreased inhibition in cells
expressing altered proteins, the tendency did not reach statistical significance compared with that in WT-expressing cells (p ¼ 0.41 by
ANOVA).and p.Asp174Gly) also showed weak signal in the cytosol,
suggesting that localization to the plasma membrane was
variably impaired in three altered proteins. Measurement
of voltage-dependent calcium currents in NG108-15 cells
also suggested impaired functions of altered Gao1. The
p.Thr191_Phe197del alteration significantly increased the
basal calcium-current density, and compared with WT-
expressing cells, cells expressing one of the three substitu-
tions (p.Thr191_Phe197del, p.Asp174Gly, or p.Gly203Thr)
showed a tendency towards weaker inhibition of
calcium currents by norepinephrine. All these data suggest
that the four GNAO1 mutations might cause loss of Gao1
function.
Our experimental data suggest that Gao function might
be most severely affected in the p.Thr191_Phe197del
altered protein. This appears to be correlated with the
severity of clinical features because individual 3 showed
both OS and involuntary movements and indeed died
during the infantile period. Therefore, she might have
had the most severe phenotype caused by a GNAO1muta-
tion. Another interesting finding is somatic mosaicism of
the c.521A>G (p.Asp174Gly) mutation in individual 2,
in whom approximately 35%–50% of cells harbored the
mutation. Somatic mosaicism of responsive genes in infan-
tile epilepsy, such as SCN1A (MIM 182389) and STXBP1,
have been reported, explaining the presence of unaffectedThe Americanor mildly affected transmitting parents.30,31 However,
individual 2 showed OS, delayed myelination, and thin
corpus callosum. Although we did not determine the
mosaic rate in brain tissues, the presence of 35%–50% of
cells harboring the GNAO1 mutation in the brain might
be sufficient to cause abnormal brain development.
It has been reported that activation of G-protein-coupled
a2 adrenergic receptors by norepinephrine attenuates
epileptiform activity in the hippocampal CA3 region.32
Gao is known to be involved in this response,
33 suggesting
that alteration of pathways mediated by a2 adrenergic
receptor and Gao might contribute to the pathogenesis
of epilepsy. Because calcium-current inhibition is a well-
known consequence of Gao-mediated signaling induced
by norepinephrine, it is possible that epileptic seizures
associated with GNAO1 mutations might be improved
by calcium-channel modulators. For example, pregabalin
and gabapentin act as selective calcium-channel
blockers,34,35 and topiramate modulates high-voltage-
activated calcium channels in dentate granule cells.36
Because our four individuals were not treated with these
drugs, it is worth administrating these three drugs for
examining putative protective effects.
In conclusion, de novo heterozygous GNAO1mutations
were identified in four individuals with epileptic encepha-
lopathy. Furthering our understanding of abnormalJournal of Human Genetics 93, 496–505, September 5, 2013 503
Gao-mediated heterotrimeric G protein signaling might
provide new insights into the pathogenesis and treatment
of epileptic encephalopathy.Supplemental Data
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